Sun Pharmaceutical Industries Ltd Share Price
(SUNPHARMA)
₹1788.8▲2.37%
as on 04:01PM, 23 Apr 2025
Sun Pharma Performance
Day's Low
Day's High
₹1,742.1Day's Price Range₹1,791.352 Week's Low
52 Week's High
₹1,377.252-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | -2.1 % |
| 3 Month Return | -4.7 % |
| 1 Year Return | + 17.7 % |
| Market Stats | |
| Previous Close | ₹1,747.40 |
| Open | ₹1,754.20 |
| Volume | 14.71L |
| Upper Circuit | ₹1,922.10 |
| Lower Circuit | ₹1,572.70 |
| Market Cap | ₹4,19,259.79Cr |
Sun Pharma Fundamentals
P/E Ratio
36.63
PEG Ratio
3.46
Market Cap
₹4,19,259.79 Cr
P/B Ratio
16.41
EPS
40.21
Dividend Yield
0.83
Sector
Pharmaceuticals
ROE
12.05
Mutual Fund Holdings of Sun Pharma
Sun Pharma Analyst Rating
based on 37 analysts
81.08%
Buy
10.81%
Hold
8.11%
Sell
Based on 37 analysts offering long term price targets for Sun Pharma. An average target of ₹2047.89
Source: S&P Global Market Intelligence
Sun Pharma Share analysis
Sun Pharma price forecast by 37 analysts
Upside of17.20%
High
₹2450
Target
₹2047.89
Low
₹1500
Sun Pharma target price ₹2047.89, a slight upside of 17.2% compared to current price of ₹1788.8. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:32.23%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:56.55%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Sun Pharmaceutical Industries Ltd
Sun Pharma Anticipates Strong US Market Growth - 23 Apr, 2025
Sun Pharmaceutical Industries is projected to deliver a 12% year-over-year growth in the US market, primarily due to the success of its specialty portfolio.Sun Pharma Shares Rise with Buy Recommendation - 20 Apr, 2025
Sun Pharmaceutical Industries Ltd shares closed at Rs.1,757.00, up 3.77%. Emkay Global recommends a Buy with a target price of Rs.2,400, suggesting a 40% upside.Sun Pharma Faces Recall Amid Regulatory Challenges - 14 Apr, 2025
Sun Pharmaceutical Industries is recalling several medicines from the US market due to manufacturing-related problems, contributing to a challenging environment for the company amid strong competition and regulatory pressures.Sun Pharma Faces Recall Amid Stock Recovery - 13 Apr, 2025
Sun Pharmaceutical Industries has seen a recovery in its stock, regaining nearly half of its earlier losses. However, it is also recalling 13,700 bottles of Gabapentin capsules due to cross-contamination concerns, which may impact investor sentiment.Sun Pharma Gains Court Approval for Leqselvi Launch - 10 Apr, 2025
Sun Pharmaceutical Industries received a favorable ruling from the U.S. Court of Appeals, lifting the injunction on Leqselvi's launch, projected to boost sales significantly in FY26 and FY27.Sun Pharma Faces Challenges from US Tariff Announcement - 09 Apr, 2025
Sun Pharmaceutical Industries Ltd is expected to face challenges due to upcoming US tariffs on pharmaceutical imports, leading to a negative trading outlook and lower stock performance.Sun Pharma Launches New Drug Amid Market Challenges - 07 Apr, 2025
Sun Pharmaceutical Industries launched FEXUCLUE for Erosive Esophagitis, demonstrating high efficacy in trials. However, shares fell 3.47% as the Nifty Pharma index hit a 10-month low.Sun Pharma Faces Tariff Concerns Amid Growth Prospects - 04 Apr, 2025
Sun Pharma shares declined due to tariff concerns after Trump's announcement, but the company is projected to achieve significant sales growth in Q4FY25, maintaining a positive outlook from analysts.Sun Pharma Shares Surge on Tariff Exemption News - 03 Apr, 2025
On April 3, 2025, Sun Pharmaceutical Industries saw its shares rise over 5% after the U.S. confirmed that Indian pharmaceutical exports would not face new tariffs. This decision is viewed positively by brokerages, highlighting Sun Pharma's resilience amid potential tariff disruptions.Sun Pharma Reports Strong Growth Amid Challenges - 02 Apr, 2025
Sun Pharmaceutical Industries Ltd reported a 10.4% revenue growth in FY24, driven by specialty drugs and a robust Indian market, despite potential tariff pressures on exports.Concerns Over Tariffs Impacting Pharma Sector - 30 Mar, 2025
India's 10% tariff on US pharma imports raises concerns among industry groups, highlighting potential cost burdens for distributors and generic manufacturers amid minimal US duties.Sun Pharma Enters Merger Agreement with Checkpoint Therapeutics - 29 Mar, 2025
Sun Pharmaceutical Industries Ltd has entered into a merger agreement with Checkpoint Therapeutics, Inc. This merger aims to facilitate the launch of UNLOXCYT in the U.S. and support marketing authorization in Europe, enhancing the company's strategic position in the oncology market.Sun Pharma Faces Challenges Amid Market Decline - 27 Mar, 2025
Sun Pharmaceutical Industries Ltd is impacted by Lyndra Therapeutics ceasing operations due to funding issues and a broader decline in Indian pharma stocks amid tariff concerns.
Insights on Sun Pharmaceutical Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 4 quarters, 12.58K Cr → 14.14K Cr (in ₹), with an average increase of 3.8% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 18.02% to 18.05% in Dec 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 8.89% to 8.92% in Dec 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 12.11% to 12.24% in Dec 2024 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 56.9% return, outperforming this stock by 39.2%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.6% return, outperforming this stock by 43.5%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Dec 2024 quarter
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 3.04K Cr → 2.90K Cr (in ₹), with an average decrease of 4.5% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, SUNPHARMA stock has moved down by -2.1%
Sun Pharma News
Wipro & 3 Other Nifty 50 Stocks with Increased FII Stake in Q4 FY25
In the latest release of the shareholding pattern of Q4 FY25, it can be seen that FIIs have increased their stake from 17.34 percent in Q3FY25 to 17.55 Percent in Q4FY25.22 Apr, 2025 10:37 AMNuvama Sets Price Targets for Top Defence Stocks BEL, HAL, and BDL
According to Nuvama, BEL is a leading supplier to all three Indian armed forces. It said that expansion of Indian Air Force (IAF) fleet and modernization drive will continue to drive growth. The brokerage has revised BELs FY25E/FY26E/FY27E EPS by 5%/-2%/+9%. On BEL shares, the brokerage has maintained BUY rating with a target price of Rs 385. At the time of writing this report around 12:30 PM on Monday (April 21), BEL shares traded 2 per cent higher at Rs 301 apiece on NSE. The target price set by Nuvama means that BEL shares have potential to yield a return of Rs 84 or 28 per cent from CMP.21 Apr, 2025 01:06 PMNuvama Prefers BEL Over HAL: Price Targets and Analysis
Nuvama Institutional Equities has come out with a report on the defence sector where it prefers shares of Bharat Electronics Ltd (BEL) over Hindustan Aeronautics Limited (HAL). The brokerage cites better execution, higher operating margins and returns on equity (RoE), faster cash conversion, higher asset turnover going forward and lower risks for picking BEL stock. Given Bharat Electronics is a relative short-cycle player in defence electronics than the mighty Hindustan Aeronautics (large systems integrator), we argue BEL should continue to trade at a premium to HALs valuation, said Nuvama. The brokerage has initiated coverage on two stocks assigning a price target of Rs 385 to BEL with a buy call. BEL consistently beats revenue and margin targets, benefits from indigenisation, and is expected to maintain premium valuation due to its short-cycle business model, said Nuvama. In the current session, the BEL stock was trading at Rs 300.90 against the previous close of Rs 295.10 on BSE. Market cap of the firm stood at Rs 2.19 lakh crore.21 Apr, 2025 12:24 PMSun Pharma Financials
Sun Pharma Index Inclusions
Sun Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 18.05% | 0.17 | |
| Mutual Funds | 12.24% | 1.02 | |
| Retail Investors | 8.92% | 0.33 | |
| Others | 6.31% |
Sun Pharma Key Indicators
Sun Pharma Valuation
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (36.63x)
April 22, 2025
Industry (53.69x)
April 22, 2025
Highest (184.63x)
August 28, 2020
Sun Pharma Earnings and Dividends
Sun Pharmaceutical Industries Ltd Earnings Results
Sun Pharmaceutical Industries Ltd’s net profit jumped 15.04% since last year same period to ₹2,903.38Cr in the Q3 2024-2025. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated -4.5% fall in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceutical Industries Ltd Dividends January,2025
In the quarter ending December 2024, Sun Pharmaceutical Industries Ltd has declared dividend of ₹10.50 - translating a dividend yield of 1.34%.
Read More about Dividends
Sun Pharma Technicals Summary
Bearish
Neutral
Bullish
Sun Pharmaceutical Industries Ltd is currently in a Bullish trading position according to technical analysis indicators.
Sun Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,19,259.79 Cr | 53.2% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| HOLD | ₹1,56,931.75 Cr | 28.91% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,09,867.99 Cr | 33.6% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹40,076.03 Cr | -0.8% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹23,904.51 Cr | -4.05% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Sun Pharma
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Revenue: ₹13,436.94Cr as on December 2024 (Q4 24)
Net Profit: ₹2,917.54Cr as on December 2024 (Q4 24)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharma |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Sun Pharmaceutical Industries Ltd
What is Sun Pharmaceutical Industries Ltd price today?
Sun Pharmaceutical Industries Ltd share price today stands at ₹1788.8, Open: ₹1754.2, Previous Close: ₹1747.4, High: ₹1791.3, Low: ₹1742.1, 52 Week High: ₹1960.35, 52 Week Low: ₹1377.2.
How to Buy Sun Pharmaceutical Industries Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Sun Pharmaceutical Industries Ltd shares
What are today's traded volumes of Sun Pharmaceutical Industries Ltd?
Today's traded volume of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is 14.71L.
What is today's market capitalisation of Sun Pharmaceutical Industries Ltd?
Today's market capitalisation of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is ₹419259.79Cr.
What is the 52 Week High and Low Range of Sun Pharmaceutical Industries Ltd?
How much percentage Sun Pharmaceutical Industries Ltd is down from its 52 Week High?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1788.8. It is down -8.75% from its 52 Week High price of ₹1960.35
How much percentage Sun Pharmaceutical Industries Ltd is up from its 52 Week low?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1788.8. It is up 29.89% from its 52 Week Low price of ₹1377.2